Chronic D2/3 agonist ropinirole treatment increases preference for uncertainty in rats regardless of baseline choice patterns

Eur J Neurosci. 2017 Jan;45(1):159-166. doi: 10.1111/ejn.13332. Epub 2016 Aug 11.

Abstract

D2/3 receptor agonists are effective treatments for Parkinson's disease (PD), but can precipitate impulse control disorders (ICDs) including gambling disorder (GD). The neurobiological mechanisms underlying this devastating side-effect of dopamine agonist replacement therapy (DRT), and any dependence on the dopamine depletion caused by PD, are unclear. It is also unclear whether previous biases towards risk or uncertainty are a risk factor for developing these ICDs. We investigated whether chronic D2/3 agonist administration (5 mg/kg/day ropinirole for 28 days) altered performance of a rat model of gambling-like behaviour, the rodent betting task (rBT), and examined if baseline behaviour predicted this behavioural change. The rBT captures individual differences in subjective preference for uncertain outcomes: animals choose between guaranteed or probabilistic reinforcement of equal expected value. Chronic ropinirole dramatically increased selection of the uncertain option in two-thirds of animals, regardless of baseline preferences. The effect on choice in the rBT was replicated in a dorsolateral striatal 6-hydroxydopamine (6-OHDA) rat model of early PD. These studies are the first to look at individual differences in response to chronic, rather than pulsatile, dosing of DRT in a rodent model of gambling behaviour. These findings suggest that DRT-induced PG may stem from increases in subjective valuation of uncertainty. Such symptoms likely arise because of changes in dopaminergic striatal signalling caused by DRT rather than from an interaction between pre-morbid behaviours or PD itself.

Keywords: GSK3β; Parkinson's disease; dopamine agonist; gambling; impulsivity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Choice Behavior / drug effects*
  • Corpus Striatum / drug effects
  • Corpus Striatum / metabolism*
  • Dopamine / metabolism
  • Dopamine Agonists / pharmacology*
  • Indoles / pharmacology*
  • Male
  • Neostriatum / metabolism
  • Oxidopamine / pharmacology
  • Parkinson Disease / drug therapy
  • Rats, Long-Evans
  • Receptors, Dopamine D2 / metabolism*
  • Receptors, Dopamine D3 / metabolism*
  • Uncertainty*

Substances

  • Dopamine Agonists
  • Indoles
  • Receptors, Dopamine D2
  • Receptors, Dopamine D3
  • ropinirole
  • Oxidopamine
  • Dopamine

Grants and funding